Israeli startup CytoReason has made its entry into Japan – the world's third-largest pharmaceutical market, upon signing a collaboration with Summit Pharmaceuticals International, the drug research and development arm of Sumitomo Corporation, one of the world's biggest general trading firms.
WHAT THEY DO
CytoReason develops computational disease models for drug discovery and development using...
